| The Month in Review | Editor's Note: When reviewing our most popular stories from June, one thing is crystal clear: TAVR remains a hugely important topic among cardiologists and other cardiology professionals. New studies and technologies are constantly emerging in the world of TAVR, and we work to cover as many of those updates as possible. Other big stories last month focused on the FDA’s approval of colchicine, the first anti-inflammatory drug for cardiovascular disease, and a Class I recall of certain Impella heart pumps. These stories highlight yet again how quickly things can change in cardiology. When will the next big story drop? Stay tuned to find out. As always, thank you for reading. - Michael Walter | Editor Editor's Note: When reviewing our most popular stories from June, one thing is crystal clear: TAVR remains a hugely important topic among cardiologists and other cardiology professionals. New studies and technologies are constantly emerging in the world of TAVR, and we work to cover as many of those updates as possible.
Other big stories last month focused on the FDA’s approval of colchicine, the first anti-inflammatory drug for cardiovascular disease, and a Class I recall of certain Impella heart pumps. These stories highlight yet again how quickly things can change in cardiology. When will the next big story drop? Stay tuned to find out. As always, thank you for reading. - Michael Walter | Editor |
| An Ohio doctor allegedly performed multiple procedures without the proper credentials. A vascular surgeon is now out of work for sharing the story with a local media outlet. An Ohio doctor allegedly performed multiple procedures without the proper credentials. A vascular surgeon is now out of work for sharing the story with a local media outlet. | | |
| The FDA's approval of colchicine, which is marketed and sold under the name Lodoco, is expected to have a big impact on cardiac care and outcomes. The FDA's approval of colchicine, which is marketed and sold under the name Lodoco, is expected to have a big impact on cardiac care and outcomes. | | |
| The coroner is concerned that the medication's rare side effects do not receive enough attention when it is prescribed to patients. The coroner is concerned that the medication's rare side effects do not receive enough attention when it is prescribed to patients. | | |
| “It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA,” according to the warning letter. These issues, the agency added, “may be symptomatic of serious problems in your firm’s manufacturing and quality management systems.” “It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA,” according to the warning letter. These issues, the agency added, “may be symptomatic of serious problems in your firm’s manufacturing and quality management systems.” | | |
| The FDA has labeled this as a Class I recall, which means using these devices can lead to significant injuries, including death. The FDA has labeled this as a Class I recall, which means using these devices can lead to significant injuries, including death. | | |
| SAVR may be even safer for low-risk patients than previously believed, according to new research published in the Journal of Thoracic and Cardiovascular Surgery. What does this tell us about patient care going forward? SAVR may be even safer for low-risk patients than previously believed, according to new research published in the Journal of Thoracic and Cardiovascular Surgery. What does this tell us about patient care going forward? | | |
| The FDA has said this is a Class I recall, which means using the devices “may cause serious injuries or death.” A total of 18 injuries have been reported so far. The FDA has said this is a Class I recall, which means using the devices “may cause serious injuries or death.” A total of 18 injuries have been reported so far. | | |
| The 88-year-old patient was originally not seen as a viable candidate for TAVR or surgery. The 88-year-old patient was originally not seen as a viable candidate for TAVR or surgery. | | |
| A new meta-analysis, published in Frontiers in Cardiovascular Medicine, focused on data from nearly 3,000 patients with severe symptomatic aortic stenosis. A new meta-analysis, published in Frontiers in Cardiovascular Medicine, focused on data from nearly 3,000 patients with severe symptomatic aortic stenosis. | | |
| Did your facility make the cut? For its 2023-2024 list, U.S. News and World Report evaluated data from 119 hospitals and surveyed thousands of pediatric specialists. Did your facility make the cut? For its 2023-2024 list, U.S. News and World Report evaluated data from 119 hospitals and surveyed thousands of pediatric specialists. | | |
| |
|
| ![]() | |
|
